Mathematical modeling of topotecan pharmacokinetics and toxicodynamics in mice

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Pharmacokinetics and Pharmacodynamics

• Publication date

  2007-09-21

• Fields of study

  Chemistry, Medicine, Mathematics

• Identifiers
  DOI 10.1007/s10928-007-9072-2PMID 17885736
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacodynamic modeling of chemotherapeutic effects: Application of a transit compartment model to characterize methotrexate effects in vitro

  2008cited by this paper
• Pharmacokinetic–Pharmacodynamic–Efficacy Analysis of Efalizumab in Patients with Moderate to Severe Psoriasis

  2005cited by this paper
• High-performance liquid chromatographic assay for the determination of total and free topotecan in the presence and absence of anti-topotecan antibodies in mouse plasma.

  2005cited by this paper
• Predictive Pharmacokinetic-Pharmacodynamic Modeling of Tumor Growth Kinetics in Xenograft Models after Administration of Anticancer Agents

  2004cited by this paper
• Clinical, pharmacokinetic and biological studies of topotecan

  2004cited by this paper
• Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors

  2004cited by this paper
• Monte Carlo Parametric Expectation Maximization (MC-PEM) Method for Analyzing Population Pharmacokinetic/Pharmacodynamic Data

  2004cited by this paper
• Pharmacokinetic-pharmacodynamic modeling of methotrexate-induced toxicity in mice.

  2003cited by this paper
• Application of pharmacokinetic-pharmacodynamic modeling to predict the kinetic and dynamic effects of anti-methotrexate antibodies in mice.

  2003cited by this paper
• Urinary and fecal excretion of topotecan in patients with malignant solid tumours

  2002cited by this paper
• The mechanism of topoisomerase I poisoning by a camptothecin analog

  2002cited by this paper
• Anti-tumour activity and toxicity of the new prodrug9-aminocamptothecin glucuronide (9ACG) in mice

  2002cited by this paper
• Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.

  2002cited by this paper
• Preclinical evaluation of the anticancer activity and toxicity of 9-nitro-20(S)-camptothecin (Rubitecan).

  2002cited by this paper
• Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer.

  2001cited by this paper
• Pharmacodynamic model of topotecan-induced time course of neutropenia.

  2001cited by this paper
• Pharmacodynamic modeling of time‐dependent transduction systems

  2001cited by this paper
• Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin.

  2001cited by this paper
• Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation.

  2001cited by this paper
• Efficacy and toxicity profile of oral topotecan in a panel of human tumour xenografts.

  2000cited by this paper
• A pharmacokinetic simulation model for ivabradine in healthy volunteers.

  2000cited by this paper
• Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.

  2000cited by this paper
• Topotecan – A Novel Topoisomerase I Inhibitor: Pharmacology and Clinical Experience

  1999cited by this paper
• Probenecid alters topotecan systemic and renal disposition by inhibiting renal tubular secretion.

  1998cited by this paper
• Animal models for studying the action of topoisomerase I targeted drugs.

  1998cited by this paper
• Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer.

  1998cited by this paper
• O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan.

  1998cited by this paper
• Clinical status and optimal use of topotecan.

  1997cited by this paper
• Topotecan: an important new drug in the management of ovarian cancer.

  1997cited by this paper
• Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan

  1997cited by this paper
• Intratibial injection of an anti-doxorubicin monoclonal antibody prevents drug-induced myelotoxicity in mice.

  1997cited by this paper
• Review of phase I clinical studies with topotecan.

  1997influential reference
• CLINICAL STATUS AND OPTIMAL USE OF TOPOTECAN

  1997cited by this paper
• Phase I Trial and Pharmacokinetic (PK) and Pharmacodynamics (PD) Study of Topotecan Using a Five‐Day Course in Children with Refractory Solid Tumors: A Pediatric Oncology Group Study

  1996cited by this paper
• Clinical Pharmacokinetics of Topotecan

  1996cited by this paper
• Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure

  1996cited by this paper
• Inverse targeting of peritoneal tumors: selective alteration of the disposition of methotrexate through the use of anti-methotrexate antibodies and antibody fragments.

  1996cited by this paper
• Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks

  1995cited by this paper
• Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.

  1995cited by this paper
• Utilization of antidrug antibody fragments for the optimization of intraperitoneal drug therapy: studies using digoxin as a model drug.

  1994cited by this paper
• Physiologic indirect response models characterize diverse types of pharmacodynamic effects

  1994cited by this paper
• Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly.

  1994cited by this paper
• Comparison of four basic models of indirect pharmacodynamic responses

  1993cited by this paper
• Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.

  1992cited by this paper
• An anti‐doxorubicin monoclonal antibody modulates kinetic and dynamic characteristics of the drug

  1992cited by this paper
• Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer.

  1992cited by this paper
• Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin.

  1988cited by this paper
• Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I.

  1985cited by this paper

• Pharmacokinetic study of Tdp1 inhibitor resulted in a significant increase in antitumor effect in the treatment of Lewis lung carcinoma in mice by its combination with topotecan.

  2023cites this paper
• Semi-Mechanism-Based Pharmacokinetic-Toxicodynamic Model of Oxaliplatin-Induced Acute and Chronic Neuropathy

  2020cites this paper
• Population Pharmacokinetic-Toxicodynamic Modeling and Simulation of Cisplatin-Induced Acute Renal Injury in Rats: Effect of Dosing Rate on Nephrotoxicity.

  2016cites this paper
• Population Pharmacokinetic–Pharmacodynamic Modeling of 5-Fluorouracil for Toxicities in Rats

  2016cites this paper
• Investigation of the Influence of Nephropathy on Monoclonal Antibody Disposition: A Pharmacokinetic Study in a Mouse Model of Diabetic Nephropathy

  2014cites this paper
• PK/TD modeling for prediction of the effects of 8C2, an anti-topotecan mAb, on topotecan-induced toxicity in mice.

  2014cites this paper
• DMD060319 1906..1913

  2014cites this paper
• Evaluation of Near IR Fluorescent Labeling of mAbs as a Tool for Tissue Distribution

  2014cites this paper
• Special Section on DMPK of Therapeutic Proteins Evaluation of Near Infrared Fluorescent Labeling of Monoclonal Antibodies as a Tool for Tissue Distribution

  2014cites this paper
• Clinical Applications of Systems Biology Approaches

  2011cites this paper
• Physiologically based pharmacokinetic model for topotecan in mice

  2011cites this paper
• Bevacizumab Effect on Topotecan Pharmacokinetics in a Murine Orthotopic Rhabdomyosarcoma Xenograft Model

  2011cites this paper
• Nonlinear turnover models for systems with physiological limits.

  2009cites this paper
• Use of an Anti-Vascular Endothelial Growth Factor Antibody in a Pharmacokinetic Strategy to Increase the Efficacy of Intraperitoneal Chemotherapy

  2009cites this paper
• Interspecies scaling of a camptothecin analogue: Human predictions for intravenous topotecan using animal data

  2008cites this paper